PPARG and urinary bladder carcinoma: Thus, GW9662 had no inhibitory effect on ciglitazone-mediated cell death; and yet it was efficient since it inhibited overexpression of the A-FABP PPARγ target when it was associated with ciglitazone in T24 bladder cancer cells (Figure 2C, left panel) as already described [18].